The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
19-Apr-22
Pending
$107 million
Target:
Syrah Resources
Acquiror:
U.S. Department of Energy
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
09-Jun-21
$310 million
Target:
Australian Unity Funds Management
Acquiror:
N/A
Advised Australian Unity Funds Management on a A$320m equity raising and A$80m cash liquidity offer for Australian Unity Healthcare Property Trust
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise
21-Apr-15
$963 million
Target:
Refinancing of syndicated bank debt facilities
Acquiror:
Primary Health Care
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
23-Apr-12
$2.0 billion
Target:
Moorebank Intermodal Terminal
Acted as independent advisor to the Australian Government in a peer review of the proposed intermodal terminal linking Sydney’s major port with Australia’s road and rail system
13-May-11
$NA
Target:
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics